Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages

Clinical and Experimental Allergy

Volumn 41, Issue 4, 2011, Pages 535-546

  Milara, J ^a,b   Navarro, A ^a   Almudever P ^a,b   Lluch, J ^a   Morcillo, E J ^b,c,d   Cortijo, J ^a,b,c  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Alveolar macrophages; Glucocorticoid resistance; Oxidative stress; Phosphodiesterase 3; Phosphodiesterase 4

Indexed keywords

8 (4 CHLOROPHENYLTHIO) CYCLIC AMP; BUDESONIDE; CIGARETTE SMOKE CONDENSATE; DEXAMETHASONE; HISTONE DEACETYLASE 1; HYDROGEN PEROXIDE; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MOTAPIZONE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PROSTAGLANDIN E2; ROLIPRAM; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTERIAL OXYGEN TENSION; ARTICLE; CARBON DIOXIDE TENSION; CELL DIFFERENTIATION; CELL STIMULATION; CELL STRAIN U937; COLORIMETRY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HORMONE RESISTANCE; HUMAN; HUMAN CELL; LUNG ALVEOLUS MACROPHAGE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; TOTAL LUNG CAPACITY;

AGED; BUDESONIDE; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; HISTONE DEACETYLASES; HUMANS; HYDROGEN PEROXIDE; INTERLEUKIN-8; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MALE; OXIDANTS; OXIDATIVE STRESS; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PYRIDAZINES; ROLIPRAM; SMOKE; TOBACCO; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952587807     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03715.x     Document Type: Article

References (34)

1. Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest 2008; 134:394-401.
2. Chung KF, Marwick JA. Molecular mechanisms of oxidative stress in airways and lungs with reference to asthma and chronic obstructive pulmonary disease. Ann N Y Acad Sci 2010; 1203:85-91.
3. Meyer M, Pahl HL. Baeuerle PA, regulation of the transcription factors NF-kappa B and AP-1 by redox changes. Chem Biol Interact 1994; 91:91-100.
4. Shapiro SD. The macrophage in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:S29-32.
5. Barnes PJ. Alveolar macrophages as orchestrators of COPD. COPD 2004; 1:59-70.
6. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153:530-4.
7. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010; 120:76-85.
8. Yang SR, Chida AS, Bauter MR et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol 2006; 291:L46-57.
9. Culpitt SV, Rogers DF, Shah P et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:24-31.
10. Ito K, Ito M, Elliott WM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352:1967-76.
11. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200:689-95.
12. To Y, Ito K, Kizawa Y et al. Targeting phosphoinositide-3-kinase-{delta} with theophylline reverses corticosteroid insensitivity COPD. Am J Respir Crit Care Med 2010; 182:897-904.
13. Hill EV, Sheppard CL, Cheung YF, Gall I, Krause E, Houslay MD. Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. Cell Signal 2006; 18:2056-69.
14. Gross NJ, Giembycz MA, Rennard SI. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 2010; 7:141-53.
15. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 1997; 121:221-31.
16. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297:267-79.
17. Winkler MT, Doster A, Jones C. Persistence and reactivation of bovine herpesvirus 1 in the tonsils of latently infected calves. J Virol 2000; 74:5337-46.
18. Hass R, Kohler L, Rehfeldt W et al. Alterations in glycosylation and lectin pattern during phorbol ester-induced differentiation of U937 cells. Cancer Res 1990; 50:323-7.
19. Tenor H, Hatzelmann A, Kupferschmidt R et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995; 25:625-33.
20. Milara J, Juan G, Ortiz JL et al. Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil. Eur J Pharm Sci 2010; 39:363-72.
21. Ortiz JL, Milara J, Juan G et al. Direct effect of cigarette smoke on human pulmonary artery tension. Pulm Pharmacol Ther 2010; 23:222-8.
22. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373:1905-17.
23. Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 2009; 157:892-906.
24. Germain N, Bertin B, Legendre A et al. Selective phosphodiesterase inhibitors modulate the activity of alveolar macrophages from sensitized guinea-pigs. Eur Respir J 1998; 12:1334-9.
25. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 1995; 25:147-53.
26. Kunkel SL, Wiggins RC, Chensue SW, Larrick J. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun 1986; 137:404-10.
27. Verhoeven GT, Garrelds IM, Hoogsteden HC, Zijlstra FJ. Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Inflamm 2001; 10:21-6.
28. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun 2004; 315:240-5.
29. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J 2001; 15:1110-2.
30. Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol 2003; 178:5-12.
31. Brown DM, Hutchison L, Donaldson K, MacKenzie SJ, Dick CA, Stone V. The effect of oxidative stress on macrophages and lung epithelial cells: the role of phosphodiesterases 1 and 4. Toxicol Lett 2007; 168:1-6.
32. Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996; 119:1255-61.
33. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol 2001; 14:767-90.
34. Wyatt TA, Schmidt SC, Rennard SI, Tuma DJ, Sisson JH. Acetaldehyde-stimulated PKC activity in airway epithelial cells treated with smoke extract from normal and smokeless cigarettes. Proc Soc Exp Biol Med 2000; 225:91-7.